Abstract:What's new? Heterogeneity in breast cancer contributes to variations in treatment effectiveness. Patient‐derived organoids (PDOs) have emerged as promising models to predict individualized drug responses, though their applicability to breast cancer remains largely unexplored. Here, the authors established a biobank of breast cancer PDOs to evaluate their feasibility in predicting patient drug response. Experiments demonstrate that the PDOs accurately inherit the histologic and genetic characteristics of the breast tumors from which they are derived. Moreover, drug susceptibility in PDOs corresponded to clinical responses in matched patients. The findings highlight the potential utility of PDOs in guiding personalized therapy for breast cancer patients. Breast cancer has become the most commonly diagnosed cancer. The intra‐ and interpatient heterogeneity induced a considerable variation in treatment efficacy. There is an urgent requirement for preclinical models to anticipate the effectiveness of individualized drug responses. Patient‐derived organoids (PDOs) can accurately recapitulate the architecture and biological characteristics of the origin tumor, making them a promising model that can overtake many limitations of cell lines and PDXs. However, it is still unclear whether PDOs‐based drug testing can benefit breast cancer patients, particularly those with tumor recurrence or treatment resistance. Fresh tumor samples were surgically resected for organoid culture. Primary tumor samples and PDOs were subsequently subjected to H&E staining, immunohistochemical (IHC) analysis, and whole‐exome sequencing (WES) to make comparisons. Drug sensitivity tests were performed to evaluate the feasibility of this model for predicting patient drug response in clinical practice. We established 75 patient‐derived breast cancer organoid models. The results of H&E staining, IHC, and WES revealed that PDOs inherited the histologic and genetic characteristics of their parental tumor tissues. The PDOs successfully predicted the patient's drug response, and most cases exhibited consistency between PDOs' drug susceptibility test results and the clinical response of the matched patient. We conclude that the breast cancer organoids platform can be a potential preclinical tool used for the selection of effective drugs and guided personalized therapies for patients with advanced breast cancer.

Gastric cancer patient-derived organoids model for the therapeutic drug screening

Patient-derived organoid culture of gastric cancer for disease modeling and drug sensitivity testing

Personalized drug screening using patient-derived organoid and its clinical relevance in gastric cancer

Establishment of patient-derived organoids and a characterization based drug discovery platform for treatment of gastric cancer

Gastrointestinal Cancer Patient Derived Organoids at the Frontier of Personalized Medicine and Drug Screening

IDDF2022-ABS-0105 Patient-derived Organoids Can Predict Chemotherapy Response of Gastric Cancers and Analysis of Its Molecular Characteristics

Patient-derived organoids as a platform for drug screening in metastatic colorectal cancer

Successful Patient-Derived Organoid Culture of Gynecologic Cancers for Disease Modeling and Drug Sensitivity Testing

Establishment of a PDTT xenograft model of gastric carcinoma and its application in personalized therapeutic regimen selection.

Ovarian Cancer Patient-Derived Organoids Used as a Model for Replicating Genetic Characteristics and Testing Drug Responsiveness: A Preliminary Study

Genomic characteristics and drug screening among organoids derived fromnon-small celllung cancer patients

Human patient derived organoids: an emerging precision medicine model for gastrointestinal cancer research

Patient‐derived organoids for personalized gallbladder cancer modelling and drug screening

Establishment of patient‐derived organoids for guiding personalized therapies in breast cancer patients

PERSONALIZED DRUG SCREENING IN PATIENT-DERIVED ORGANOIDS OF BILIARY TRACT CANCER AND ITS CLINICAL APPLICATION

Paired Organoids from Primary Gastric Cancer and Lymphatic Metastasis Are Useful for Personalized Medicine

Creation and Development of Patient-Derived Organoids for Therapeutic Screening in Solid Cancer

Promising preclinical patient-derived organoid (PDO) and xenograft (PDX) models in upper gastrointestinal cancers: progress and challenges

Patient-derived organoids of non-small cells lung cancer and their application for drug screening

The combination of breast cancer PDO and mini‐PDX platform for drug screening and individualized treatment

Colorectal Cancer Tissue-Originated Spheroids Reveal Tumor Intrinsic Signaling Pathways and Mimic Patient Clinical Chemotherapeutic Response As a Rapid and Valid Model